Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Thursday, even as CEO Zhi Hong said the company is looking to expand into another therapeutic area.

Brii launched in May with $260 million and three initial partnerships

Read the full 504 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers